2017_SBRT_Course Book

Approved targeted drugs

Radio-Oncology

Medical Oncology

Cetuximab Panatimumab Bevacizumab Trastuzumab Ipilimumab Pembrolizumab Nivolumab Afatinib Lapatinib Axatinib Sorafenib Sunitinib

Cetuximab

Head & Neck

Colorectal Breast Pancreas NSCLC Glioblastoma Renal cell cancer GIST Thyroid Head & Neck ….

Unsuccessful

Cetuximab

RCHT Head & Neck

Rectal cancer

Esophageal cancer

NSCLC

Pazopanib Vandetanib ….

Bevacizumab

Glioblastoma

Ø Combining targeted drugs & conventionally fractionated radio(chemo)therapy has been an unsuccessful strategy

07.09.17 ESTRO SBRT COURSE 2017 - Matthias Guckenberger

5

/

Adoption of SBRT in the (oligo)- metastatic situation

International Survey of 1007 Radiation Oncologists

Adoption of SBRT for oligometastasis

Overall Western Europe 61% 76%

Lewis American Journal of Clinical Oncology 2015

Ø SBRT for oligo-metastasis has become a standard of care

07.09.17 ESTRO SBRT COURSE 2017 - Matthias Guckenberger

6

/